KING DRUG COMPANY OF FLORENCE, INC vs. CEPHALON, INC., ET AL

  1. October 29, 2019

    ​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

    A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.

  2. August 28, 2017

    Provigil Buyers Lose Cert. In Pay-For-Delay Suit

    A Pennsylvania federal judge denied certification Monday for purchasers who say Ranbaxy Laboratories Ltd. inked pay-for-delay deals with Provigil maker Cephalon, ruing that a proposed class of about two dozen does not satisfy numerosity requirements.

  3. February 03, 2017

    Mylan Inks $96.5M Pay-For-Delay Deal With Cephalon Buyers

    Mylan Pharmaceuticals Inc. has agreed to pay $96.5 million to settle with direct purchasers in pay-for-delay litigation over Cephalon's narcolepsy drug Provigil, according to a court filing in Pennsylvania federal court.

  4. January 26, 2016

    3rd Circ. Stays Provigil Pay-For-Delay Trial During Cert. Appeal

    The Third Circuit agreed Monday to stay an upcoming trial in a class action accusing Mylan and Ranbaxy Laboratories of inking pay-for-delay deals with Cephalon to keep generic versions of narcolepsy drug Provigil off the market while the appeals court weighs the decision to certify the class.

  5. January 22, 2016

    Drug Buyers Must Play Nice At Trial, Provigil Judge Says

    Days before drugmakers including Cephalon Inc. are set to face a jury over an alleged pay-for-delay scheme involving its sleep-disorder medicine Provigil, a Pennsylvania federal judge has ruled the group suing isn't allowed to use certain prejudicial terms, bring up past guilty pleas or discuss pharmaceutical industry policies.

  6. January 15, 2016

    Ranbaxy Can't Split Antitrust Claims From Provigil Trial

    Ranbaxy Laboratories Inc. lost a bid to split certain claims from an upcoming trial in pay-for-delay litigation over sleep-disorder medicine Provigil when a Pennsylvania federal judge found Friday that the claims involve overlapping issues and can be heard together.

  7. January 06, 2016

    Apotex Loses Bid To Block Cephalon Experts In Provigil Trial

    A Pennsylvania federal judge on Wednesday refused to bar certain testimony from Cephalon Inc.'s economic experts in an upcoming pay-for-delay trial over narcolepsy drug Provigil, despite claims from Apotex that the experts offered opinions outside their area of expertise.

  8. January 04, 2016

    Provigil Antitrust Trial Should Be Postponed, Drug Cos. Say

    Mylan and Ranbaxy Laboratories doubled down Monday on their request that the Third Circuit pause an upcoming pay-for-delay trial over Cephalon Inc.'s narcolepsy drug Provigil while the appeals court hears their challenge to class certification, saying such a stay is necessary.

  9. December 22, 2015

    Drug Cos. Ask 3rd Circ. To Halt Trial For Class Cert. Fight

    Mylan Inc. and Ranbaxy Laboratories Inc. have urged the Third Circuit to halt an upcoming pay-for-delay trial over Cephalon Inc.'s narcolepsy drug Provigil while the appeals court hears their challenge to class certification, arguing Monday that the district court doesn't have jurisdiction over the case while the original appeal is pending.

  10. December 17, 2015

    Mylan, Ranbaxy Can't Halt Pay-For-Delay Suits Pending Appeal

    A Pennsylvania federal judge on Thursday refused to pause pay-for-delay litigation against Mylan Inc. and Ranbaxy Laboratories Inc. over Cephalon Inc.'s narcolepsy drug Provigil while the Third Circuit hears the drug companies' appeal of a class certification order.